glp-1 stock market Drugs Size to Hit USD 132.79 Bn by 2035 Betting on GLP-1 - by

Regulatory & Legal Status AOD-9604 has no FDA-approved therapeutic use and has never been cleared for human consumption by any government health authority worldwide it exists in a pre-clinical/discontinued-development status, which is the basis for its banned classification

Regional People with overweight, all classes of obesity, and T2D spotlighting the frequent concurrence of the two conditions Obesity x T2D overlap Wegovy and Zepbound are not FDA-approved to treat type 2 diabetes, but in clinical trials, in addition to losing weight, patients saw improvements in blood glucose levels

(1) Liu, J

Semaglutide aids in weight loss by suppressing appetite and reduces food cravings in addition to improving glycemic control